Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

The RNA Binding Protein Musashi 2 Is up-Regulated in the Proliferative B-Cell Fraction of Chronic Lymphocytic Leukemia Clones

Florencia Palacios, PhD, Xiao-Jie Yan, MD PhD, Jaqueline C. Barrientos, MD, Jonathan E. Kolitz, MD, Steven L. Allen, MD, Kanti R. Rai, MD, Nicholas Chiorazzi, MD

Blood (2015) 126 (23): 4149.

https://doi.org/10.1182/blood.V126.23.4149.4149

Published: 2015

Journal Articles

Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results

Sven de Vos, MD PhD, Nina D. Wagner-Johnston, MD, Steven E. Coutre, MD, Ian Flinn, Marshall T. Schreeder, MD, Nathan Fowler, MD, Jeff P. Sharman, MD, Ralph V. Boccia, MD, Jaqueline C. Barrientos, MD, Kanti R. Rai, MD, Thomas E Boyd, MD, Richard R. Furman, MD, Leanne M. Holes, Yeonhee Kim, PhD, Wayne R. Godfrey, MD, John P. Leonard, MD

Blood (2014) 124 (21): 3063.

https://doi.org/10.1182/blood.V124.21.3063.3063

Published: 2014

Journal Articles

Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE TM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Blood (2014) 124 (21): 3331.

https://doi.org/10.1182/blood.V124.21.3331.3331

Published: 2014

Journal Articles

Chronic Lymphocytic Leukemia Patients Exhibit Expanded Functional Granulocyte-like Myeloid Derived Suppressor Cells

Gerardo Ferrer, PhD, Rita Simone, PhD, Sonia Marsilio, PhD, Stefano Vergani, Andrea Nicola Mazzarello, PhD, Shih-Shih Chen, PhD, Xiao Jie Yan, PhD, Barbara Sherry, PhD, Jaqueline C. Barrientos, MD, Jonathan E. Kolitz, MD, Steven L. Allen, MD, Kanti R. Rai, MD, Nicholas Chiorazzi, MD

Blood (2014) 124 (21): 3279.

https://doi.org/10.1182/blood.V124.21.3279.3279

Published: 2014

Journal Articles

Autoimmune Hemolytic Anemia and Immune Mediated Thrombocytopenia in the Phase III RESONATE TM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including a Case Report

Marco Montillo, MD, Susan O'Brien, MD, Alessandra Tedeschi, MD, Peter Hillmen, MB, ChB, PhD, Claire Dearden, MD, Devinder Gill, MD, Jennifer R. Brown, MD PhD, Jaqueline C. Barrientos, MD, Stephen Mulligan, MBBS, MD FRACP, FRCPA, Richard R. Furman, MD, Florence Cymbalista, MD, Clara Plascencia, Stephen Chang, PhD, Emily Hsu, PhD, Danelle F. James, MD MAS, John C. Byrd, MD

Blood (2014) 124 (21): 5654.

https://doi.org/10.1182/blood.V124.21.5654.5654

Published: 2014

Journal Articles

A Systematic Search Into The Role Of IGHV Gene Replacement In Shaping The Immunoglobulin Repertoire Of Chronic Lymphocytic Leukemia

Sophia Yancopoulos, PhD, Xiao-Jie Yan, MD PhD, Andreas Agathangelidis, Wentian Li, Ph.D., Chrysoula Belessi, Paolo Ghia, MD, PhD, Richard Rosenquist, MD, PhD, Frederic Davi, MD, PhD, David Graham Oscier, MD, Sarka Pospisilova, Panagiotis Panagiotidis, MD, Lin Huang, PhD, Zhixin Zhang, PhD, Steven L. Allen, MD, Jaqueline C. Barrientos, MD, Jonathan E. Kolitz, MD, Kanti R. Rai, MD, Kostas Stamatopoulos, MD, Nicholas Chiorazzi, MD

Blood (2013) 122 (21): 4129.

https://doi.org/10.1182/blood.V122.21.4129.4129

Published: 2013

Journal Articles

Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study

Jennifer R Brown, MD, PhD, Jaqueline C. Barrientos, MD, Paul M. Barr, MD, Ian Flinn, MD, PhD, Jan A. Burger, MD, PhD, Zeena Salman, Fong Clow, ScD, Danelle F. James, MD, Thorsten Graef, MD, PhD, Jonathan W. Friedberg, MD, Kanti R. Rai, M.D., Susan O'Brien, MD

Blood (2013) 122 (21): 525.

https://doi.org/10.1182/blood.V122.21.525.525

Published: 2013

Journal Articles

A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Jeff Sharman, MD, Sven de Vos, MD, PhD, John P. Leonard, MD, Richard R. Furman, MD, Steven E. Coutre, MD, Ian W. Flinn, MD, PhD, Marshall T. Schreeder, Jaqueline C. Barrientos, MD, Nina D. Wagner-Johnston, Thomas Boyd, MD, Nathan H. Fowler, MD, Leanne Holes, Brian Lannutti, David Johnson, Thomas M. Jahn, Langdon L Miller

Blood (2011) 118 (21): 1787.

https://doi.org/10.1182/blood.V118.21.1787.1787

Published: 2011

Journal Articles

Engraftment of CLL-Derived T Cells in NSG Mice Is Feasible, Can Support CLL Cell Proliferation, and Eliminates the Need for Third Party Antigen Presenting Cells

Piers EM Patten, BSc, MBBCh, PhD, Shih-Shih Chen, Ph.D., Davide Bagnara, Ph.D., Rita Simone, PhD, Sonia Marsilio, PhD, Timothy Tong, Jaqueline C. Barrientos, MD, Jonathan E. Kolitz, MD, Steven L. Allen, M.D., Kanti R Rai, MD, Nicholas Chiorazzi, M.D.

Blood (2011) 118 (21): 975.

https://doi.org/10.1182/blood.V118.21.975.975

Published: 2011

Journal Articles

Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium

Danelle F. James, M.D., Jennifer R. Brown, MD, PhD, Lillian Werner, William G. Wierda, MD, PhD, Jaqueline C. Barrientos, MD, Januario Castro, MD, Andrew Greaves, Laura Z. Rassenti, Ph.D., Kanti R. Rai, MD, Donna Neuberg, ScD, Thomas J. Kipps, M.D., Ph.D

Blood (2011) 118 (21): 291.

https://doi.org/10.1182/blood.V118.21.291.291

Published: 2011

Journal Articles

A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Cal-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Previously Treated, Indolent Non-Hodgkin Lymphoma (iNHL)

Sven de Vos, MD, PhD, Marshall T. Schreeder, Ian W. Flinn, MD, PhD, Steven E. Coutre, MD, John P. Leonard, MD, Nina D. Wagner-Johnston, Nathan H. Fowler, MD, Ralph V. Boccia, MD, Jaqueline C. Barrientos, MD, Thomas Boyd, MD, Jeff Sharman, MD, Leanne Holes, Brian Lannutti, Dave M. Johnson, Thomas M. Jahn, Langdon L Miller

Blood (2011) 118 (21): 2699.

https://doi.org/10.1182/blood.V118.21.2699.2699

Published: 2011

Journal Articles

TLR-9 and B-Cell Antigen Receptor Triggering of Primary B Cells From Mantle Cell Lymphoma Induce Cell Proliferation and Telomerase Activity,

Sonal Temburni, MS, Ryon M. Andersen, B.A., Steven L. Allen, M.D., Jaqueline C. Barrientos, MD, Jonathan E. Kolitz, MD, Kanti R. Rai, M.D., Nicholas Chiorazzi, M.D., Rajendra N Damle, PhD

Blood (2011) 118 (21): 3690.

https://doi.org/10.1182/blood.V118.21.3690.3690

Published: 2011

NARROW

The RNA Binding Protein Musashi 2 Is up-Regulated in the Proliferative B-Cell Fraction of Chronic Lymphocytic Leukemia Clones

Durable Responses Following Treatment with the PI3K-Delta Inhibitor Idelalisib in Combination with Rituximab, Bendamustine, or Both, in Recurrent Indolent Non-Hodgkin Lymphoma: Phase I/II Results

Updated Efficacy Including Genetic and Clinical Subgroup Analysis and Overall Safety in the Phase 3 RESONATE TM Trial of Ibrutinib Versus Ofatumumab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia Patients Exhibit Expanded Functional Granulocyte-like Myeloid Derived Suppressor Cells

Autoimmune Hemolytic Anemia and Immune Mediated Thrombocytopenia in the Phase III RESONATE TM Study of Ibrutinib Vs Ofatumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Including a Case Report

A Systematic Search Into The Role Of IGHV Gene Replacement In Shaping The Immunoglobulin Repertoire Of Chronic Lymphocytic Leukemia

Ibrutinib In Combination With Bendamustine and Rituximab Is Active and Tolerable In Patients With Relapsed/Refractory CLL/SLL: Final Results Of a Phase 1b Study

A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Engraftment of CLL-Derived T Cells in NSG Mice Is Feasible, Can Support CLL Cell Proliferation, and Eliminates the Need for Third Party Antigen Presenting Cells

Lenalidomide and Rituximab for the Initial Treatment of Patients with Chronic Lymphocytic Leukemia (CLL) A Multicenter Study of the CLL Research Consortium

A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Cal-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Previously Treated, Indolent Non-Hodgkin Lymphoma (iNHL)

TLR-9 and B-Cell Antigen Receptor Triggering of Primary B Cells From Mantle Cell Lymphoma Induce Cell Proliferation and Telomerase Activity,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only